In obese and overweight men with erectile dysfunction, GLP-1 receptor agonists (GLP-1 RAs) produce weight-loss-dependent increases in total and calculated free testosterone while improving body composition and metabolic profile—key drivers of obesity-associated hypogonadism. SGLT2 inhibitors similarly improve metabolic markers and erectile function, but their effect on androgen levels remains contradictory across studies. Notably, testosterone replacement therapy (TRT) outperformed GLP-1 RAs specifically on orgasm quality and sexual satisfaction domains.
This analysis reframes GLP-1 RAs not merely as metabolic drugs but as indirect androgen modulators—a meaningful conceptual shift. The testosterone rise appears mechanistically downstream of fat mass reduction rather than direct hypothalamic-pituitary-gonadal axis stimulation, which explains why gonadotropin levels remain largely unchanged. That distinction matters: it suggests benefit is proportional to weight lost, not pharmacological potency per se.
The clinical calculus here is genuinely interesting. TRT improves sexual endpoints more robustly in the short term, yet carries cardiovascular neutrality at best—a liability in the metabolically compromised men most likely to have hypogonadism. GLP-1 RAs offer proven cardiovascular mortality reduction, making them a compelling first-line option for this high-risk phenotype despite more modest sexual outcomes. Limitations are significant: this is a review synthesis, not a randomized head-to-head trial, and long-term androgen trajectory data under GLP-1 RA therapy remain sparse. For men whose primary complaint is orgasmic dysfunction, TRT likely remains superior.
